Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03475875 · ClinicalTrials.gov registry record · Phase 2

Contact Lenses With New UV-blocker Manufactured With Different Techniques

A Phase 2 study, sponsored by Johnson & Johnson Vision Care.

Completed
Registry status
Phase 2
Development phase
92
Enrollment target

NCT03475875 is a Phase 2 study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 92 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03475875, a Phase 2 study, has completed, sponsored by Johnson & Johnson Vision Care.

COMPLETED
Registry status
Phase 2
Development phase
92 participants
Enrollment target

Study Summary

This study is a randomized, 4-visit, double-masked, 2x3 bilateral crossover, dispensing trial. The study lenses will be worn as daily wear (DW) for a period of two weeks each with one of the study lenses being worn twice. Each study lens is expected to be worn at least five (5) days per week for at least six (6) hours per day worn. There will be no washout period between study lenses.

Interventions

  • DEVICE senofilcon A TEST Lens
  • DEVICE senofilcon A CONTROL Lens

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2018-02-19
Est. Completion 2018-04-18
Phase Phase 2

Sponsor

Johnson & Johnson Vision Care

142 total trials

What the Registry Record Tells You About NCT03475875

The ClinicalTrials.gov registry entry for NCT03475875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Vision Care, which has 142 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which senofilcon A TEST Lens is the first listed.

NCT03475875 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03475875 about?

NCT03475875 is a clinical study titled "Contact Lenses With New UV-blocker Manufactured With Different Techniques". This study is a randomized, 4-visit, double-masked, 2x3 bilateral crossover, dispensing trial. The study lenses will be worn as daily wear (DW) for a period of two weeks each with one of the study lenses being worn twice. Each study lens is expected to be worn at least five (5) days per week for at ...

What is the current status of trial NCT03475875?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2018-02-19. Estimated completion is 2018-04-18.

What interventions are being tested in trial NCT03475875?

The interventions under investigation include: senofilcon A TEST Lens (DEVICE), senofilcon A CONTROL Lens (DEVICE).

Who is sponsoring clinical trial NCT03475875?

This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.